Dr. Sanjiv Agarwala highlighted melanoma immunotherapy progress, with long-term cures in 40–50% of metastatic cases. Nivolumab + anti-LAG-3 is effective, while some triplets failed. TILs help refractory cases. Anti-PD-1 is standard adjuvant therapy; neoadjuvant ipilimumab/nivolumab boosts event-free survival.